Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Holoclar

Brand: 
NICE TA: 467
Indication: Treating limbal stem cell deficiency after eye burns (NICE TA467)
Disease category: Eye
Commissioning responsibility: NHS England
PbR excluded: Yes

Background

Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells) is recommended as an option in people with moderate to severe limbal stem cell deficiency after eye burns, only if:

•it is only used to treat 1 eye and
•people have already had a conjunctival limbal autograft or
•there is not enough tissue for a conjunctival limbal autograft or it is contraindicated and
•the company provides it with the discount agreed in the patient access scheme.

Moderate to severe limbal stem cell deficiency is defined by the presence of superficial corneal neovascularisation in at least 2 corneal quadrants, with central corneal involvement, and severely impaired visual acuity.

Holoclar is recommended in people with moderate to severe limbal stem cell deficiency after eye burns for treating both eyes only:

•in the context of research and
•when there is not enough tissue for a conjunctival limbal autograft.

Such research should be designed to generate robust evidence of the clinical- and cost-effectiveness of Holoclar in treating 2 eyes in people who do not have enough tissue for a conjunctival limbal autograft.

Recommendation

LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA467 - Holoclar for treating limbal stem cell deficiency after eye burns

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red